The medical technology firm Senseonics (NYSEAMERICAN:SENS) has seen its stock make a strong move this morning during premarket trading after it announced encouraging results with regards to its glucose monitoring system.
The stock shot up by 30% this morning and that continues a strong run from Senseonics over the past six months. It should be noted that for most of last year the stock had been trading at levels below 50 cents a share but at the time of writing, it is trading at $2.94 a share.
The company is currently focused on developing glucose monitoring systems that can be implanted into patients. This morning the company announced that the results from the 180-day study of the Eversense CGM System were positive. It should be noted that the findings from the study are going to be the basis on which Senseonics is going to be able to make the premarket application in Europe and the United States.